Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget
Executive Summary
Bristol-Myers Squibb's partnerships with AstraZeneca and Pfizer to develop several late-stage compounds may provide the company with $2 billion to support its research and development initiatives, the firm said
You may also be interested in...
Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
The April 1-2 meeting of the Endocrinologic & Metabolic Drugs Advisory Committee ended in equivocal results for the sponsors involved, but sends an unequivocal message of hope to diabetes drug development companies: the new cardiovascular safety bar adopted by FDA in December is surmountable
Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
The April 1-2 meeting of the Endocrinologic & Metabolic Drugs Advisory Committee ended in equivocal results for the sponsors involved, but sends an unequivocal message of hope to diabetes drug development companies: the new cardiovascular safety bar adopted by FDA in December is surmountable
Pfizer Restructures For A More Flexible Future
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care and emerging markets